Engineered immune cells show promise against stubborn lymphoma
NCT ID NCT03105336
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 16 times
Summary
This study tested a treatment called axicabtagene ciloleucel, which uses a patient's own immune cells that are modified in a lab to attack cancer. It involved 159 adults with follicular or marginal zone lymphoma that had not responded to at least two prior treatments. The main goal was to see how many patients had their tumors shrink or disappear. While the therapy can be effective, it is not a cure and patients may need ongoing monitoring or additional treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234, United States
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Centre Hospitalier Régional Universitaire de Lille
Lille, 59037, France
-
Columbia University Medical Center
New York, New York, 10032, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
H Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Ohio State University Medical Center
Cleveland, Ohio, 44106, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Miami Hospital and Clinics
Miami, Florida, 33136, United States
-
University of Rochester Medical Center (URMC)
Rochester, New York, 14642, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.